Prelude Capital Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Prelude Capital Management’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-66,445	Closed	-$2.55M	–	1476
2023 Q2	$2.55M	Buy	+66,445	New	+$1.71M	0.17%	150
2023 Q1	–	Sell	-10,502	Closed	-$275K	–	1600
2022 Q4	$275K	Buy	+10,502	New	+$233K	0.01%	824
2018 Q1	–	Sell	-18	Closed	-$1K	–	1778
2017 Q4	$1K	Sell	18 -1	-5%	-$44	﹤0.01%	1310
2017 Q3	$1K	Buy	+19	New	+$1.13K	﹤0.01%	1572
2015 Q3	–	Sell	-140	Closed	-$21K	–	1876
2015 Q2	$21K	Buy	+140	New	+$23.1K	﹤0.01%	1355

Prelude Capital Management's KDNY Position: Q3 2023 in Review

Prelude Capital Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 66,445 shares — an estimated $2.55M sold.

Prelude Capital Management first reported a position in KDNY in Q2 2015 and held it in 5 quarters. The position peaked at $2.55M in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

Prelude Capital Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Prelude Capital Management sold 66,445 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $2.55M.
Prelude Capital Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2015 and held it in 5 quarters.
Prelude Capital Management's Chinook Therapeutics, Inc. Common Stock position peaked at $2.55M in Q2 2023.
2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Prelude Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.